ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2066 entries already.
When the time comes for a biopharma company to outsource its production, or to get support for the development of a new project, the pool of available CDMOs is quite deep. Everyone knows the big players, but maybe they are not suitable for everyone. They have proven expertise but as it happens with big organisations, they are usually not very flexible with increased indirect costs.
German CureVac N.V. has withdrawn its application for market approval of its COVID-19 vaccine candidate and will focus on the development of a second-generation vaccine.
Abstract: This white paper explores how to leverage hot melt extrusion solutions for small molecules.
James Brook, since June 2021 Head of Europe, Africa and Middle-East at Tigermed, about clinical research, and plans for his new role.
Sino Biological, a biotechnology company which provides biological research reagents and related technical contract research services, will be featured on Worldwide Business with kathy ireland, airing on FOX Business Network, Bloomberg International and other outlets as sponsored content. Hosted by business mogul Kathy Ireland, this award-winning television series takes an in-depth look at companies around the world currently impacting different sectors of business and society. Dr. Rob Burgess, Chief Business Officer for Sino Biological, will be interviewed.
What started in 2013 as an attempt – to offer experts in analytical and microbiological quality control, contract laboratories, representatives from authorities and service providers an
industry event and a platform for exchanging knowledge and experience – has now become a firmly established date in the events calendar.
Pharma giant AstraZeneca has submitted data to the US Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of its antibody duo AZD7442.
Cell and Gene Therapy Processing?Personalised tumour treatments are expensive. This particularly applies to individual cancer therapies based on gene-modified T cells. Currently, they are produced manually or, at best, in a partially-automated process. In a collaboration project ProCell for Patient, two hospitals are currently working with Optima Pharma to develop an automated unit for the decentralised production of a CAR-T cell product in treatment centres.
The success of any adoptive cell therapy lies in how effectively and selectively engineered immune cells interact and kill cancer cells. Functional phenomics enables insights that can dramatically accelerate the development of next-gen cell therapies. evorion biotechnologies brings functional phenomics to pharma and biotech partners via exclusive access to a unique, proprietary pipeline for in-depth multi-modal analysis of thousands of cell-cell interactions at single-cell resolution.
BionTech SE, which has been very successful in the field of corona vaccines, is starting phase II tests with its colorectal cancer candidate BNT122.